Icon Plc (NASDAQ:ICLR) – Equities research analysts at William Blair lowered their FY2018 earnings per share (EPS) estimates for Icon in a research note issued to investors on Tuesday. William Blair analyst J. Kreger now expects that the medical research company will post earnings of $5.99 per share for the year, down from their previous forecast of $6.04. William Blair also issued estimates for Icon’s Q4 2018 earnings at $1.61 EPS, FY2019 earnings at $6.74 EPS and FY2020 earnings at $7.55 EPS.
Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.32 by $0.03. Icon had a return on equity of 28.42% and a net margin of 16.37%. The firm had revenue of $440.30 million during the quarter, compared to analysts’ expectations of $438.09 million. During the same period in the prior year, the business earned $1.19 EPS. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year.
Icon (NASDAQ ICLR) traded down $3.10 on Thursday, hitting $114.71. The stock had a trading volume of 247,100 shares, compared to its average volume of 292,737. Icon has a 1 year low of $76.46 and a 1 year high of $124.48. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.90 and a quick ratio of 1.90. The stock has a market cap of $6,150.00, a PE ratio of 22.27, a P/E/G ratio of 1.63 and a beta of 0.61.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GRATRY & Co LLC lifted its holdings in Icon by 5.1% in the 3rd quarter. GRATRY & Co LLC now owns 30,144 shares of the medical research company’s stock worth $3,433,000 after buying an additional 1,474 shares during the period. GSA Capital Partners LLP lifted its holdings in Icon by 116.3% in the 2nd quarter. GSA Capital Partners LLP now owns 9,337 shares of the medical research company’s stock worth $913,000 after buying an additional 5,020 shares during the period. BT Investment Management Ltd purchased a new stake in Icon in the 3rd quarter worth approximately $325,000. Insight Capital Research & Management Inc. purchased a new stake in Icon in the 3rd quarter worth approximately $1,359,000. Finally, NorthCoast Asset Management LLC lifted its holdings in Icon by 23.4% in the 3rd quarter. NorthCoast Asset Management LLC now owns 18,016 shares of the medical research company’s stock worth $2,052,000 after buying an additional 3,419 shares during the period. Institutional investors and hedge funds own 89.66% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This article was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2018/01/12/icon-plc-iclr-forecasted-to-earn-fy2018-earnings-of-5-99-per-share.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.